Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Non-cash Items (2020 - 2023)

Cytek Biosciences' Non-cash Items history spans 4 years, with the latest figure at $4.4 million for Q2 2023.

  • For Q2 2023, Non-cash Items rose 32.11% year-over-year to $4.4 million; the TTM value through Jun 2023 reached $4.4 million, up 32.11%, while the annual FY2022 figure was $4.2 million, 97.14% down from the prior year.
  • Non-cash Items reached $4.4 million in Q2 2023 per CTKB's latest filing, roughly flat from $4.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $147.6 million in Q4 2021 to a low of $1.0 million in Q2 2020.
  • Average Non-cash Items over 4 years is $18.6 million, with a median of $3.7 million recorded in 2022.
  • Peak YoY movement for Non-cash Items: skyrocketed 1194.37% in 2021, then tumbled 74.8% in 2022.
  • A 4-year view of Non-cash Items shows it stood at $11.4 million in 2020, then surged by 1194.37% to $147.6 million in 2021, then crashed by 74.8% to $37.2 million in 2022, then tumbled by 88.22% to $4.4 million in 2023.
  • Per Business Quant, the three most recent readings for CTKB's Non-cash Items are $4.4 million (Q2 2023), $4.4 million (Q1 2023), and $37.2 million (Q4 2022).